Literature DB >> 29296794

Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis.

Larisa Broglie1,2, Lauren Pommert2,3, Sridhar Rao4, Monica Thakar1,2, Rachel Phelan1,2, David Margolis1,2, Julie Talano1,2.   

Abstract

Optimal salvage therapy for refractory HLH is unknown.In our patient, ruxolitinib treatment led to clinical remission of refractory HLH.

Entities:  

Year:  2017        PMID： 29296794      PMCID： PMC5728466          DOI： 10.1182/bloodadvances.2017007526

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  21 in total

1.  Alpha-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis.

Authors:  Maren Tomaske; Oliver Amon; Axel Bosk; Rupert Handgretinger; E Marion Schneider; Dietrich Niethammer
Journal:  Med Pediatr Oncol       Date:  2002-02

Review 2.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

3.  Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.

Authors:  Naresh Punwani; Peggy Scherle; Robert Flores; Jack Shi; Jinjin Liang; Swamy Yeleswaram; Richard Levy; William Williams; Alice Gottlieb
Journal:  J Am Acad Dermatol       Date:  2012-01-24       Impact factor: 11.527

4.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

5.  Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis.

Authors:  Tomoko Henzan; Koji Nagafuji; Hiroshi Tsukamoto; Toshihiro Miyamoto; Hisashi Gondo; Shinsaku Imashuku; Mine Harada
Journal:  Am J Hematol       Date:  2006-01       Impact factor: 10.047

6.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

7.  Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

Authors:  William J Sandborn; Subrata Ghosh; Julian Panes; Ivana Vranic; Chinyu Su; Samantha Rousell; Wojciech Niezychowski
Journal:  N Engl J Med       Date:  2012-08-16       Impact factor: 91.245

8.  Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.

Authors:  Srdan Verstovsek; Hagop M Kantarjian; Zeev Estrov; Jorge E Cortes; Deborah A Thomas; Tapan Kadia; Sherry Pierce; Elias Jabbour; Gautham Borthakur; Elisa Rumi; Ester Pungolino; Enrica Morra; Domenica Caramazza; Mario Cazzola; Francesco Passamonti
Journal:  Blood       Date:  2012-06-20       Impact factor: 22.113

Review 9.  Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience.

Authors:  Rebecca A Marsh; Michael B Jordan; Julie-An Talano; Kim E Nichols; Ashish Kumar; Ahmed Naqvi; Sarah R Vaiselbuh
Journal:  Pediatr Blood Cancer       Date:  2016-10-27       Impact factor: 3.167

10.  Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Authors:  R Zeiser; A Burchert; C Lengerke; M Verbeek; K Maas-Bauer; S K Metzelder; S Spoerl; M Ditschkowski; M Ecsedi; K Sockel; F Ayuk; S Ajib; F S de Fontbrune; I-K Na; L Penter; U Holtick; D Wolf; E Schuler; E Meyer; P Apostolova; H Bertz; R Marks; M Lübbert; R Wäsch; C Scheid; F Stölzel; R Ordemann; G Bug; G Kobbe; R Negrin; M Brune; A Spyridonidis; A Schmitt-Gräff; W van der Velden; G Huls; S Mielke; G U Grigoleit; J Kuball; R Flynn; G Ihorst; J Du; B R Blazar; R Arnold; N Kröger; J Passweg; J Halter; G Socié; D Beelen; C Peschel; A Neubauer; J Finke; J Duyster; N von Bubnoff
Journal:  Leukemia       Date:  2015-07-31       Impact factor: 11.528
View more
  36 in total

Review 1.  Cellular therapy: Immune-related complications.

Authors:  Joseph H Oved; David M Barrett; David T Teachey
Journal:  Immunol Rev       Date:  2019-07       Impact factor: 12.988

2.  Possible roads to improve hemophagocytic lymphohistiocytosis outcome.

Authors:  Pietro Merli; Michael B Jordan; Franco Locatelli
Journal:  Blood Adv       Date:  2020-12-22

3.  Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.

Authors:  Asra Ahmed; Samuel A Merrill; Fares Alsawah; Paula Bockenstedt; Erica Campagnaro; Sumana Devata; Scott D Gitlin; Mark Kaminski; Alice Cusick; Tycel Phillips; Suman Sood; Moshe Talpaz; Albert Quiery; Philip S Boonstra; Ryan A Wilcox
Journal:  Lancet Haematol       Date:  2019-09-16       Impact factor: 18.959

4.  Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis.

Authors:  Romain Lévy; Mathieu Fusaro; Frédéric Guerin; Ahmed Chetouani; Despina Moshous; Alain Fischer; Geneviève de Saint Basile; Fernando E Sepulveda; Bénédicte Neven
Journal:  Blood Adv       Date:  2020-04-14

Review 5.  Pediatric hemophagocytic lymphohistiocytosis.

Authors:  Scott W Canna; Rebecca A Marsh
Journal:  Blood       Date:  2020-04-16       Impact factor: 22.113

6.  Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib.

Authors:  Scott R Goldsmith; Sana Saif Ur Rehman; Cara L Shirai; Kiran Vij; John F DiPersio
Journal:  Blood Adv       Date:  2019-12-10

Review 7.  Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management.

Authors:  Lauren A Henderson; Randy Q Cron
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

8.  Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis.

Authors:  Sabrin Albeituni; Katherine C Verbist; Paige E Tedrick; Heather Tillman; Jennifer Picarsic; Rachel Bassett; Kim E Nichols
Journal:  Blood       Date:  2019-04-23       Impact factor: 22.113

9.  Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases.

Authors:  Adriana A de Jesus; Yangfeng Hou; Stephen Brooks; Louise Malle; Angelique Biancotto; Yan Huang; Katherine R Calvo; Bernadette Marrero; Susan Moir; Andrew J Oler; Zuoming Deng; Gina A Montealegre Sanchez; Amina Ahmed; Eric Allenspach; Bita Arabshahi; Edward Behrens; Susanne Benseler; Liliana Bezrodnik; Sharon Bout-Tabaku; AnneMarie C Brescia; Diane Brown; Jon M Burnham; Maria Soledad Caldirola; Ruy Carrasco; Alice Y Chan; Rolando Cimaz; Paul Dancey; Jason Dare; Marietta DeGuzman; Victoria Dimitriades; Ian Ferguson; Polly Ferguson; Laura Finn; Marco Gattorno; Alexei A Grom; Eric P Hanson; Philip J Hashkes; Christian M Hedrich; Ronit Herzog; Gerd Horneff; Rita Jerath; Elizabeth Kessler; Hanna Kim; Daniel J Kingsbury; Ronald M Laxer; Pui Y Lee; Min Ae Lee-Kirsch; Laura Lewandowski; Suzanne Li; Vibke Lilleby; Vafa Mammadova; Lakshmi N Moorthy; Gulnara Nasrullayeva; Kathleen M O'Neil; Karen Onel; Seza Ozen; Nancy Pan; Pascal Pillet; Daniela Gp Piotto; Marilynn G Punaro; Andreas Reiff; Adam Reinhardt; Lisa G Rider; Rafael Rivas-Chacon; Tova Ronis; Angela Rösen-Wolff; Johannes Roth; Natasha Mckerran Ruth; Marite Rygg; Heinrike Schmeling; Grant Schulert; Christiaan Scott; Gisella Seminario; Andrew Shulman; Vidya Sivaraman; Mary Beth Son; Yuriy Stepanovskiy; Elizabeth Stringer; Sara Taber; Maria Teresa Terreri; Cynthia Tifft; Troy Torgerson; Laura Tosi; Annet Van Royen-Kerkhof; Theresa Wampler Muskardin; Scott W Canna; Raphaela Goldbach-Mansky
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 10.  Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO).

Authors:  Michael B Jordan; Carl E Allen; Jay Greenberg; Michael Henry; Michelle L Hermiston; Ashish Kumar; Melissa Hines; Olive Eckstein; Stephan Ladisch; Kim E Nichols; Carlos Rodriguez-Galindo; Birte Wistinghausen; Kenneth L McClain
Journal:  Pediatr Blood Cancer       Date:  2019-07-24       Impact factor: 3.167
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.